Finance

Lists
CRBP:NASDAQ
Corbus Pharmaceuticals Holdings Inc
$9.87
+1.33%
(+0.13) 1D
Aug 7, 1:11:15 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBP...
Open
$9.74
High
$10.23
Low
$9.74
Mkt. cap
182.87M
Avg. vol.
369.46K
Volume
166.49K
52-wk high
$20.56
52-wk low
$7.12
EPS
-$5.81
Beta
2.59
Shares outstanding
18.53M
No. of employees
36
Open
$9.74
High
$10.23
Low
$9.74
Mkt. cap
182.87M
Avg. vol.
369.46K
Volume
166.49K
52-wk high
$20.56
52-wk low
$7.12
EPS
-$5.81
Beta
2.59
Shares outstanding
18.53M
No. of employees
36
News stories
From sources across the web
About Corbus Pharmaceuticals Holdings Inc
CEO-
Employees36
FoundedJan 1, 2009
Headquarters-
SectorBiotechnology
Websitecorbuspharma.com
Analyst ratings
Based on 9 analysts giving stock ratings to CRBP in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for CRBP in the last 3 months.
Highest
Current $9.87
$48.00 (+386.32%)
Average
$37.38 (+278.72%)
Lowest
$30.00 (+203.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
Leland Gershell
Oppenheimer
Buy
Reiterated
$48.00
+386.3%
08/07/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$35.00
+254.6%
08/07/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
08/06/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$34.00
+244.5%
06/23/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$52.00
+426.8%
06/17/2026
Paul Jeng
Guggenheim
Buy
Maintained
$45.00
+355.9%
06/02/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$30.00
+204%
05/27/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
$38.00
+285%
05/26/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$36.00
+264.7%
05/26/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$38.00
+285%
05/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
$33.00
+234.3%
05/12/2026
Unknown Analyst
B. Riley Securities
Buy
Reiterated
$28.00
+183.7%
04/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
15.19M
20.86M
18.41M
19.82M
Cost of revenue
15.19M
20.86M
18.41M
19.82M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.96M
3.56M
3.56M
4.48M
Operating expense
3.96M
3.56M
3.56M
4.48M
Total operating expenses
19.15M
24.42M
21.97M
24.30M
Operating income
-19.15M
-24.42M
-21.97M
-24.30M
Other non operating income
176.00K
-50.00K
-1.10M
-67.00K
EBT including unusual items
-17.66M
-23.34M
-20.56M
-22.97M
EBT excluding unusual items
-17.66M
-23.34M
-21.66M
-22.97M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.66M
-23.34M
-20.56M
-22.97M
Net profit margin
-
-
-
-
Earnings per share
-1.44
-1.90
-1.25
-1.23
Interest and investment income
1.31M
1.12M
1.41M
1.40M
Interest expense
-
-
-
-
Net interest expenses
1.31M
1.12M
1.41M
1.40M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.10M
-24.37M
-21.92M
-24.26M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps